Endocrine Society encouraged by Lilly’s new lower-priced insulin

Eli Lilly and Company recently announced its authorized generic version of lispro is now available at a 50 percent lower list price than the brand name version, Humalog U-100. The Society is pleased at this step toward improving access to affordable insulin. According to a press release from the company, the generic lispro can now be ordered in pharmacies. This announcement is welcome news for patients who are currently paying out of pocket for Humalog U-100. According to Lilly, some insurers will be including generic lispro on their formularies.

For patients who wish to change to the generic version of lispro, prescribers should write for lispro insulin, rather than Humalog. Patients with questions about generic lispro and insulin affordability can contact the Lilly Diabetes Solution Center at (833) 808-1234.

The Endocrine Society continues to urge policymakers, drug manufacturers, insurance companies and pharmacy benefit managers to work together to stop the spiraling cost of insulin and other medications that has led to an ever-growing patchwork of complex, confusing, and difficult to access safety net programs.

About the Endocrine Society
Endocrinologists are at the core of solving the most pressing health problems of our time, including diabetes, obesity, infertility, bone health, and hormone-related cancers. The Endocrine Society is the largest global organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

With more than 18,000 members in 133 countries, the Society serves as the voice of the endocrine field. Through its renowned journals and ENDO, the world's largest endocrine meeting, the Society accelerates hormone research, advances clinical excellence in endocrinology, and advocates for evidence-based policies on behalf of the global endocrine community. To learn more, visit our online newsroom.